The collaboration combines Qiagen’s tertiary analysis solution with OGT’s SureSeq NGS panels
OGT, a specialist in genomic research and diagnostic solutions, and Qiagen Digital Insights (QDI), a provider of genomic interpretation and analysis tools, have partnered to build on OGT's bioinformatics capabilities. This partnership integrates Qiagen's tertiary analysis solution, QCI Interpret, with OGT's SureSeq NGS panels.
Designed for variant interpretation and clinical reporting, QCI Interpret provides AI-powered classifications with oncologist-reviewed summaries and transparent evidence links. The partnership enables SureSeq NGS panel users to have access to high-confidence genomic insights and efficient, scalable reporting from sample to result.
QDI has created an expert-curated knowledge base of genomic and bioinformatic content, acting as the foundation of QCI Interpret. The combination of the clinical precision of expert curation with the speed and scalability of AI-powered automation enables QCI Interpret labs to provide high-confidence variant interpretation and reporting.
QCI Interpret gives SureSeq customers transparent variant classifications, oncologist-reviewed summaries, and on-demand interpretations.
SureSeq NGS products from OGT have been conceived with hybridisation-based detection capabilities to allow clinical labs to achieve comprehensive genomic profiling of their samples and reduce any risks of missing variants. The labs also receive access to an end-to-end workflow for better-informed and confident insights due to Qiagen's proprietary software.
Gareth Thomson, executive vice president of Commercial Operations at OGT, said, “We are delighted to be partnering with QIAGEN Digital Insights to allow OGT’s customers to package their SureSeq NGS panels with QIAGEN Digital Insights tertiary analysis software creating an end-to-end NGS workflow with access to the world’s largest knowledge base, increasing customers' confidence in variant classification. This partnership is an important demonstration of OGT’s commitment to providing the most relevant and impactful oncology insights”.
Nitin Sood, senior vice president and head of Life Sciences at Qiagen, said, “We are pleased to partner with OGT to deliver an even greater impact to labs worldwide. This collaboration reinforces QIAGEN Digital Insights’ global leadership in variant interpretation to deliver scalable, collaborative and cutting-edge solutions for precision medicine. As labs face mounting challenges with the complexity and volume of NGS testing, QDI is uniquely positioned to support SureSeq workflows with transparent variant classifications, oncologist-reviewed insights and flexible reporting. This helps customers to scale confidently, reduce turnaround times, and improve outcomes for patients.”
